AKCEA-ANGPTL3-LRx

Phase 2Small molecule

AKCEA-ANGPTL3-LRx is one of 31 small molecule programs targeting Familial Partial Lipodystrophy. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Familial Partial LipodystrophyActive, not recruiting

Homozygous Familial HypercholesterolemiaActive, not recruiting

Familial Partial LipodystrophyPhase 2

Active, not recruiting

Homozygous Familial HypercholesterolemiaPhase 2

Active, not recruiting

Competition

Competitive Landscape

31 competitors in Homozygous Familial Hypercholesterolemia

#DrugCompanyPhaseTrials

EVKEEZA

Regeneron

Phase 3

4 2

Leqvio

Novartis

Phase 3

3 3

Crestor

AstraZeneca

Phase 3

3 4

Praluent

Regeneron

Phase 3

2 5

Lescol

Novartis

Phase 3

1 6

Lipitor

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Phase 3

2 7

Zocor

OOrganon and Co

Phase 3

2 8

Pravachol

KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

Phase 3

1 9

Altoprev

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Phase 3

1 10

Tricor

JJagotec

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Familial Chylomicronemia Syndrome1 trial

Phase 2 Study of AKCEA-ANGPTL3-LRx (ISIS 703802) in Participants With Familial Chylomicronemia Syndrome (FCS)

Completed·AAkcea Therapeutics·Phase 2·NCT03360747·3 enrolled

Homozygous Familial Hypercholesterolemia1 trial

Study of AKCEA-ANGPTL3-LRX (ISIS 703802) in Patients With Homozygous Familial Hypercholesterolemia (HoFH)

Withdrawn·AAkcea Therapeutics·Phase 2·NCT03455777

Familial Partial Lipodystrophy1 trial

Study of AKCEA-ANGPTL3-LRx (ISIS 703802) in Participants With Familial Partial Lipodystrophy (FPL)

Completed·AAkcea Therapeutics·Phase 2·NCT03514420·4 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for AKCEA-ANGPTL3-LRx. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — AKCEA-ANGPTL3-LRx compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for AKCEA-ANGPTL3-LRx. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Akcea Therapeutics company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: AAkcea Therapeutics

AKCEA-ANGPTL3-LRx

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Familial Chylomicronemia Syndrome1 trial

Homozygous Familial Hypercholesterolemia1 trial

Familial Partial Lipodystrophy1 trial

References

Drug Info

Quick Facts

Related News